Funding and platform commitments point to continued investment in early and scalable therapeutic development. Marrow Therapeutics unveiled $173M to support a 'Trojan Horse' delivery approach for blood disorder drugs, targeting sickle cell disease and beta thalassemia with an emphasis on manufacturing and dosing advantages. In parallel, Isomorphic secured a record $5B series round ahead of naming a development candidate, reinforcing momentum around AI-assisted drug design and pipeline build-outs.